Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fushen Granule + fecal microbiota
- Development stage
- Preclinical
- Lead developer
- First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
- Modality
- Small Molecules, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Peptides, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Fushen Granule + fecal microbiota is a combination therapy consisting of a Traditional Chinese Medicine (TCM) herbal preparation and fecal microbiota transplantation (FMT). Fushen Granule is an improved granule based on the classic "Fushen Formula," composed of eight herbal ingredients including *Astragalus membranaceus* and *Salvia miltiorrhiza*. It is primarily used to treat intestinal dysfunction in patients with end-stage renal disease (ESRD) and those undergoing peritoneal dialysis. When combined with FMT, the therapy targets the "renal-intestinal axis" to restore gut microbiome homeostasis. The mechanism involves increasing the abundance of beneficial bacteria such as *Lactobacillus* and the Firmicutes/Bacteroidetes ratio, while reducing the production of gut-derived uremic toxins like indoxyl sulfate (IS) and p-cresol sulfate (PCS). This intervention repairs the intestinal mucosal barrier, reduces serum endotoxin and D-lactate levels, and slows the progression of chronic renal failure (CRF) and renal fibrosis.
- Other names
- Fushen FormulaFushen GranulesFMT of Fushen Granule fecal bacteria
02
Targets
IS (Indoxyl sulfate)
Beyond the preview
Go deeper on Fushen Granule + fecal microbiota.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fushen Granule + fecal microbiota.